Moderna's Cancer Vaccine Win Fuels Broad Push Across Tumor Types

Moderna said positive Phase III results for intismeran, its investigational personalized cancer vaccine in adjuvant melanoma, support extending its T-cell-priming approach to multiple tumor types. The results strengthen the company’s oncology-platform outlook, though no efficacy figures, regulatory timeline, or commercial guidance were disclosed.